Inauguration of new integrated Asian Veterinary R&D Center in China
Boehringer Ingelheim confirms its commitment to growth in China with the investment of 19 million euros in its new integrated Asian Veterinary Research & Development Center
Microbial systems are ideal for synthesizing smaller and non-glycosylated proteins, complementing mammalian cell processes for larger proteins like monoclonal antibodies.
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
About Our Business| Bioxcellence | Boehringer Ingelheim
BioXcellence, reliable contract development & manufacturing partner to the pharmaceutical industry. A trusted partner through the Lifecyle of your product.
Boehringer Ingelheim annouces 2020 BVDzero Case Awards
Boehringer Ingelheim is announcing the 2020 ‘BVDzero Case Awards’ are now open for applications. The bi-annual awards reflect the long-term commitment to promoting the health and well-being of farm animals.